MarketPulse

Anktiva

31 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

ImmunityBio Stock Plummets 21% After FDA Warning Over Anktiva Cancer Claims

ImmunityBio faces securities fraud lawsuit after FDA warning letter alleges false Anktiva promotional claims. Stock dropped 21% to $7.42.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

ImmunityBio Hit with Class Action Over Anktiva Claims; Deadline Looms for Investors

Class action lawsuit filed against ImmunityBio over Anktiva misstatement claims. Lead plaintiff deadline May 26, 2026.
IBRXRGCsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

ImmunityBio Stock Crashes 21% Following FDA Warning on Cancer Therapy

ImmunityBio faces securities fraud lawsuit after FDA warning letter on Anktiva cancer therapy. Stock plummeted to $7.42. Class action period open through May 26.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

ImmunityBio Plummets 21% After FDA Warning Letter Over Misleading Cancer Drug Claims

ImmunityBio faces securities lawsuit after FDA warning letter over misleading Anktiva efficacy claims. Stock plunged 21%, erasing $2 billion in market value.
IBRXsecurities class actionstock price decline
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

ImmunityBio Faces Securities Fraud Class Action Over Anktiva Misrepresentations

Class action lawsuit filed against $IBRX alleging securities fraud over false statements regarding Anktiva capabilities. Investors who purchased shares January-March 2026 may be eligible.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

ImmunityBio Plummets 21% After FDA Flags Cancer Drug Misleading Claims

ImmunityBio shares plunge 21% after FDA flags misleading cancer drug claims; $2B market cap erased. Securities lawsuit filed.
IBRXstock declinesecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

ImmunityBio Stock Plummets 21% After FDA Warning on Cancer Drug Claims

ImmunityBio faces securities fraud lawsuit following FDA warning letter about misleading Anktiva advertisements. Stock dropped to $7.42 per share.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

ImmunityBio Investors Face May 26 Deadline in Securities Fraud Class Action

ImmunityBio investors must act by May 26, 2026 to claim lead plaintiff status in securities fraud class action alleging executive misstatements about Anktiva drug capabilities.
IBRXsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

ImmunityBio Faces Class Action Over False Claims About Anktiva Cancer Treatment

Class action lawsuit filed against $IBRX over alleged misleading statements regarding Anktiva capabilities between January-March 2026. Lead plaintiff deadline May 26.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kessler Topaz Meltzer & Check, Llp

ImmunityBio Hit With Securities Fraud Suit Over Cancer Drug Claims

ImmunityBio faces class action lawsuit alleging false Anktiva claims. Stock plummeted 21% after FDA warning letter. Lead plaintiff deadline May 26, 2026.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

ImmunityBio Investors Face May Deadline in Securities Class Action Over Overstated Drug Claims

Rosen Law Firm urges ImmunityBio investors with $100K+ losses to pursue claims by May 26 deadline in class action alleging material misstatements about Anktiva capabilities.
IBRXinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Geller Rudman & Dowd Llp

ImmunityBio Faces Securities Class Action Over Anktiva's False FDA Claims

ImmunityBio faces securities lawsuit over allegedly misleading Anktiva promotional materials. Stock fell 21% after FDA warning letter; investors can seek lead plaintiff status.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

ImmunityBio Plummets 21% After FDA Flags Cancer Drug Misleading Claims

ImmunityBio faces securities lawsuit after FDA warning over misleading Anktiva cancer claims. Stock drops 21%, erasing $2B market cap.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

ImmunityBio Hit With Class Action Over Anktiva Misstatements

Class action lawsuit filed against $IBRX alleging false statements about Anktiva capabilities and business prospects during January-March 2026.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

ImmunityBio Faces Securities Fraud Class Action After FDA Warning, Stock Crashes 21%

ImmunityBio faces securities fraud lawsuit after FDA warns of false cancer cure claims for Anktiva, stock crashes 21% to $7.42.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

ImmunityBio Stock Plunges 21% After FDA Warning on Cancer Drug Claims

ImmunityBio faces securities fraud lawsuit following FDA warning letter about misleading Anktiva advertisements. Stock fell to $7.42; investors have until May 26 to file claims.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

ImmunityBio Faces Major Securities Lawsuit Over FDA Warning on Drug Claims

ImmunityBio faces securities lawsuit after FDA warning letter regarding misleading efficacy claims for immunotherapy drug Anktiva, triggering 21% stock plunge.
IBRXinvestor lossessecurities class action
BenzingaBenzinga··Vandana Singh

ImmunityBio Surges on Strong Q1 Revenue, But FDA Warning Clouds Outlook

ImmunityBio stock rallied 7% after reporting $44.2M in Q1 product revenue, up 168% YoY, despite FDA warning over Anktiva marketing claims.
IBRXAnktivaImmunityBio
BenzingaBenzinga··Vandana Singh

FDA Warns ImmunityBio Over Anktiva Cancer Claims Despite Strong 750% Sales Surge

FDA flagged ImmunityBio for unsupported Anktiva cancer cure claims. Company implemented corrective measures while reporting 750% unit volume growth and $38.29M quarterly revenue.
IBRXsales growthregulatory compliance
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

ImmunityBio Faces Securities Class Action Over Anktiva Claims

Rosen Law Firm initiates securities lawsuit against $IBRX over alleged false statements regarding Anktiva capabilities. Lead plaintiff deadline: May 26, 2026.
IBRXsecurities class actionlead plaintiff